ArticleAAPS PharmSciTech2025
Combination Drug Product of Amorphous Solid Dispersion Show Extended Supersaturation and Enhanced Dissolution.
Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synergistic role of monoacyl phospholipids and precipitation inhibitor in ternary solid dispersions: a case study of Aripiprazole.Drug delivery and translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Investigation on multidrug formulations is increasing, because of enhanced efficacy and patient compliance. The two antiparasitic drugs Albendazole (ABZ) and mebendazole (MBZ) combination is well reported in the clinical research. However, ABZ-MBZ drug combination do not progressed well due to in vivo drug-drug interaction of precipitation of either drug leading to sub-therapeutic concentration in systemic circulation. Herein, we studied the effect of various cellulosic polymers on the supersaturation behaviour of ABZ and MBZ in combination. We screened a large group of cellulosic polymers and selected HPMCAS on the basis of supersaturation behaviour, drug-polymer solubility, and drug particle size. An amorphous solid dispersion was developed comprising ABZ-MBZ and HPMCAS. Drug amorphization was confirmed using thermal and crystallographic technique. In kinetic solubility, the ternary ASD enhanced the solubility of ABZ/MBZ by 1.88/3.52-fold (pH 1.2), 146.08/201.38-fold (pH 6.8) and 182.47/50.38-fold (water) as compared to crystalline ABZ and MBZ. In vitro release study supports kinetic solubility data as in ternary ASD the fraction drug release of ABZ/MBZ was increased by 2.22/2.55-fold (pH 1.2), 22.82/25.98-fold (pH 6.8) and 18.5/12-fold (water) in comparison to crystalline drugs. AUC
Indexed as
Identifiers
40447945What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.